<DOC>
	<DOCNO>NCT00599937</DOCNO>
	<brief_summary>Objectives trial ass optimal timing chemotherapy ATRA role maintenance therapy .</brief_summary>
	<brief_title>APL93 : Timing CxT Role Maintenance</brief_title>
	<detailed_description>Induction treatment stratify age initial WBC count . Patients ≤65 year age WBC count le 5,000/µL randomized receive reference ATRA treatment previous trial ( APL91 trial ) { Fenaux , 1993 # 2088 } , ie , 45 mg/m2/d ATRA follow CT ( ATRA→CT group ) ATRA plus CT ( ATRA+CT ) . In ATRA→CT group , patient receive 45 mg/m2/d ATRA orally CR , maximum 90 day . After CR achievement , receive course 60 mg/m2/d daunorubicin ( DNR ) 3 day 200 mg/m2/d AraC 7 day ( course I ) . However , course I add ATRA WBC count increase great 6,000/µL , 10,000/µL , 15,000/µL day 5 , 10 , 15 ATRA treatment , respectively , be-cause , experience , patient risk ATRA syndrome threshold { de Botton , 2003 # 1127 ; De Botton , 1998 # 1604 } . Patients randomized ATRA+CT group receive combination ATRA CT , course I CT start day 3 ATRA treatment . Patients WBC count great 5,000/µL presentation ( irrespective age ) patient 66 75 year age WBC count ≤ 5,000/µL ran-domized receive ATRA plus CT course I day 1 ( high WBC group ) schedule ATRA→CT group ( elderly group ) , respectively . Treatment coagulopathy induction phase base platelet support maintain platelet count level great 50,000 /µL disappea-rance coagulopathy . The use heparin , tranexamic acid , fresh frozen plasma , fibrinogen transfusion optional . CR patient receive 2 CT consolidation course , include course II ( identical course I ) course III , consist 45 mg/m2/d DNR 3 day 1 g/m2 AraC every 12 hour 4 day . The elderly group receive course II . Three 4 week hematological recovery consolidation CT , patient still CR randomize receive receive intermittent ATRA ( 45 mg/m2/d , 15 day every 3 month ) receive receive continuous CT 6 mercaptopurine ( 90 mg/m2/d , orally ) methotrexate ( 15 mg/m2/wk , oral-ly ) , accord 2-by-2 factorial design stratify initial induction treatment group . Maintenance treatment schedule 2 year . Randomizations induc-tion maintenance , stratify center , perform centralize tele-phone assignment procedure .</detailed_description>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>1 . Diagnosis APL , base morphology criterion 2 . Age 75 year less ; 3 . Written informed consent . Diagnosis subsequently confirm presence ( 15 ; 17 ) PMLRAR gene rearrangement . In absence ( 15 ; 17 ) analysis rearrangement could make , review initial marrow slide independent morphologist mandatory .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>APL</keyword>
</DOC>